Virological, serological and biochemical outcomes through 3 years of entecavir treatment in nucleoside-naive Chinese chronic hepatitis B patients

• Published in: Journal of viral hepatitis 2010-03, Vol.17 (s1), p.51-58
• Main Authors: Yao, G. B., Ren, H., Xu, D. Z., Zhou, X. Q., Jia, J. D., Wang, Y. M., Chen, C. W.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Alanine Transaminase - blood; Antiviral Agents - administration & dosage; Asian Continental Ancestry Group; China; chronic hepatitis B; DNA, Viral - blood; Double-Blind Method; entecavir; Guanine - administration & dosage; Guanine - analogs & derivatives; HBeAg seroconversion; HBV DNA; Hepatitis B e Antigens - blood; hepatitis B virus; Hepatitis B, Chronic - drug therapy; Humans; Lamivudine - administration & dosage; Male; Middle Aged; resistant mutant; Treatment Outcome; Viral Load; Young Adult
• ISSN: 1352-0504; 1365-2893
• DOI: 10.1111/j.1365-2893.2010.01271.x

Hepatitis B virus (HBV) infection has a high prevalence in China. Entecavir has shown superior efficacy over lamivudine in Chinese nucleoside‐naive chronic hepatitis B (CHB) patients over 48 weeks, with continued clinical benefit to 96 weeks. The present study evaluates the long‐term efficacy of entecavir in Chinese CHB patients who continued entecavir treatment for 144 weeks. Patients receiving either entecavir 0.5 mg/day (n = 258) or lamivudine 100 mg/day (n = 261) entered the initial 96‐week randomized, double‐blind, controlled efficacy study. Patients who did not achieve a consolidated response [HBV DNA